Gastric Cancer Global Clinical Trials Review, H2, 2017

Date: August 23, 2017
Pages: 1335
Price:
US$ 2,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G10290CC8EDEN
Leaflet:

Download PDF Leaflet

Gastric Cancer Global Clinical Trials Review, H2, 2017
Gastric Cancer Global Clinical Trials Review, H2, 2017

SUMMARY

GlobalData's clinical trial report, “Gastric Cancer Global Clinical Trials Review, H2, 2017' provides an overview of Gastric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Gastric Cancer Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Gastric Cancer
Aug 10, 2017: CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial
Aug 03, 2017: Zymeworks Appoints Dr. Natalie Sacks to its Board of Directors
Jul 19, 2017: Athenex, Announces Commencement of Patient Enrollment for Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer
Jul 17, 2017: Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
Jul 17, 2017: Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer
Jun 26, 2017: Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer
Jun 04, 2017: New Monotherapy Data for Mercks KEYTRUDA (pembrolizumab) in Heavily Pre-Treated Patients with Advanced Gastric Cancer to be Presented at 2017 ASCO Annual Meeting
Jun 04, 2017: Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting
Jun 03, 2017: Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
Jun 01, 2017: Aslan Pharmaceuticals Receives Clinical Trial Authorisation To Initiate Pivotal Study Of Varlitinib In Gastric Cancer
Clinical Trial Profile Snapshots
Appendix 1332
Abbreviations 1332
Definitions 1332
Research Methodology 1333
Secondary Research 1333
About GlobalData 1334
Contact Us 1334
Disclaimer 1334
Source 1335

LIST OF TABLES

Gastric Cancer Therapeutics, Global, Clinical Trials by Region, 2017
Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017
Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017
Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2017
Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries, 2017
Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017
Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017
Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2017
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017
Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2017
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017
Gastric Cancer Therapeutics, Global, Clinical Trials by Phase, 2017
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2017
Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017

LIST OF FIGURES

Gastric Cancer Therapeutics, Global, Clinical Trials by Region (%), 2017
Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017
Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017
Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017
Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2017
Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017
Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017
Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2017
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2017
Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017
Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2017
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2017
Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017
Gastric Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2017
Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2017
Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017
Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017
GlobalData Methodology 1333

COMPANIES MENTIONED

F. Hoffmann-La Roche Ltd
Sanofi
AstraZeneca Plc
Otsuka Holdings Co Ltd
Pfizer Inc
Eli Lilly and Company
Sarah Cannon Research Institute LLC
Bristol-Myers Squibb Company
Novartis AG
Merck & Co Inc
Skip to top


Ask Your Question

Gastric Cancer Global Clinical Trials Review, H2, 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: